IKT News
Archived Headlines
- US IPO Week Ahead: Biotechs break the post-election ice in a 3 IPO week 11/06/20
- Neurodegenerative disease biotech Inhibikase Therapeutics lowers proposed deal size by 40% ahead of $15 million IPO 11/03/20
- US IPO Week Ahead: Chinese fintech, pool supplies, and auto insurance lead a diverse 15 IPO week 10/23/20
- Neurodegenerative disease biotech Inhibikase Therapeutics sets terms for $25 million IPO 09/15/20
- US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week 07/24/20
See more
US IPO Week Ahead: Foreign issuers dominate a 4 IPO week
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
Neurodegenerative disease biotech Inhibikase Therapeutics prices IPO at $10 low end
Inhibikase Therapeutics, an early stage biotech developing kinase inhibitors for Parkinson's and related disorders, raised $18 million by offering 1.8 million shares at $10, the low end of the range of $10 to $12. The company originally filed in July 2020 but...read more
US IPO Weekly Recap: Postponements abound as DoorDash joins the IPO pipeline
Eight SPACs went public this past week but no IPOs, as all three scheduled deals postponed or withdrew. New filing activity picked up, led by long-awaited delivery service unicorn DoorDash (DASH), and several launches indicate increased...read more
Neurodegenerative disease biotech Inhibikase Therapeutics postpones $15 million IPO
Inhibikase Therapeutics, an early stage biotech developing kinase inhibitors for Parkinson's and related disorders, postponed its IPO on Friday. It had planned to raise $15 million by offering 1.4 million shares at a price range of $10 to $12. The Atlanta,...read more